Journal Article

Impact of CYP3A5 Polymorphisms on Pediatric Asthma Outcomes

Lamb, John G., Reilly, Christopher A., Stone, Bryan L., Nkoy, Flory L., Zhu, Angela, Rower, Joseph E., Deering-Rice, Cassandra E.

2024

Overview

Genetic variation among inhaled corticosteroid (ICS)-metabolizing enzymes may affect asthma control, but evidence is limited. This study tested the hypothesis that single-nucleotide polymorphisms (SNPs) in Cytochrome P450 3A5 (CYP3A5) would affect asthma outcomes. Patients aged 2–18 years with persistent asthma were recruited to use the electronic AsthmaTracker (e-AT), a self-monitoring tool that records weekly asthma control, medication use, and asthma outcomes. A subset of patients provided saliva samples for SNP analysis and participated in a pharmacokinetic study. Multivariable regression analysis adjusted for age, sex, race, and ethnicity was used to evaluate the impact of CYP3A5 SNPs on asthma outcomes, including asthma control (measured using the asthma symptom tracker, a modified version of the asthma control test or ACT), exacerbations, and hospital admissions. Plasma corticosteroid and cortisol concentrations post-ICS dosing were also assayed using liquid chromatography–tandem mass spectrometry. Of the 751 patients using the e-AT, 166 (22.1%) provided saliva samples and 16 completed the PK study. The e-AT cohort was 65.1% male, and 89.6% White, 6.0% Native Hawaiian, 1.2% Black, 1.2% Native American, 1.8% of unknown race, and 15.7% Hispanic/Latino; the median age was 8.35 (IQR: 5.51–11.3) years. CYP3A5*3/*3 frequency was 75.8% in White subjects, 50% in Native Hawaiians and 76.9% in Hispanic/Latino subjects. Compared with CYP3A5*3/*3, the CYP3A5*1/*x genotype was associated with reduced weekly asthma control (OR: 0.98; 95% CI: 0.97–0.98; p < 0.001), increased exacerbations (OR: 6.43; 95% CI: 4.56–9.07; p < 0.001), and increased asthma hospitalizations (OR: 1.66; 95% CI: 1.43–1.93; p < 0.001); analysis of 3/*3, *1/*1 and *1/*3 separately showed an allelic copy effect. Finally, PK analysis post-ICS dosing suggested muted changes in cortisol concentrations for patients with the CYP3A5*3/*3 genotype, as opposed to an effect on ICS PK. Detection of CYP3A5*3/3, CYPA35*1/*3, and CYP3A5*1/*1 could impact inhaled steroid treatment strategies for asthma in the future.

• Publisher: MDPI AG,MDPI
• Subject: Adolescent / Adrenal Cortex Hormones - administration & dosage / Adrenal Cortex Hormones - pharmacokinetics / Adrenal Cortex Hormones - therapeutic use / Age / Asthma / Asthma - drug therapy / Asthma - genetics / Asthma in children / Child / Child, Preschool / Chronic diseases / Chronic illnesses / Cytochrome P-450 CYP3A - genetics / Cytochrome P-450 CYP3A - metabolism / Enzymes / Ethnicity / Female / Females / Genetic aspects / Genotype / Genotype & phenotype / Hospitalization / Humans / Hydrocortisone - blood / Male / Metabolism / Metabolites / Patient admissions / Pediatrics / Polymorphism, Single Nucleotide / Population / Respiratory agents / Saliva - metabolism / Treatment Outcome / White people